Findings from a phase III clinical trial for advanced lung cancer patients could help oncologists better predict which patients are likely to receive the most benefit from immunotherapy as a first-line treatment based on the unique molecular characteristics of their tumor, according to a new study.

Source: First-line immunotherapy treatment can improve survival for subset of lung cancer patients


David Cottle

UBB Owner & Administrator